SPECIAL NOTICE
99 -- Explore contribution of non-neuronal cells to effects of drugs of abuse
- Notice Date
- 1/27/2012
- Notice Type
- Special Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- National Institutes of HealthNational Institute on Drug AbuseBethesdaMD20892-7511
- ZIP Code
- 20892-7511
- E-Mail Address
-
LINDSAY, CAROL A
(clindsay@intra.nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse (NIDA), Intramural Research Program (IRP) intends to solicit, negotiate and award a purchase order on a noncompetitive basis with Regents of the University of Colorado, 3100 Marine Street, Rm 479, 572 UCB, Boulder, CO 80303. This project will continue from time of award to September 30, 2012.This acquisition is to advance a project that explores the potential contribution of non-neuronal cells (glia, endothelial cells) to the reinforcing effects of drugs of abuse. The project explores the role of toll-like receptor 4 (TLR4) as a key receptor on these non-neuronal cells that causes their rapid proinflammatory activation in response to abused drugs. The involvement of TLR4 will be assessed using TLR4 inhibitors microinjected into brains of rats and mice. The project focuses on major drugs of abuse whose reinforcing properties are traditionally thought to result from direct interactions with neuronal cells in the mesocortical dopamine system. This acquisition will facilitate studies on the modulation of drug reinforcement by non-neuronal cells by fulfilling three objectives. The first objective will be to assess which mesocortical sites are key in mediating TLR4 effects on acute behavioral, chronic behavioral, and neurochemical outcomes of stimulant drugs. The second objective will be to assess the immunohistochemistry of immediate-early genes (IEGs) and epigenetic changes induced by blockade of TLR4. A third objective will be to determine what proinflammatory changes occur in response to the drug in the key mesocortical sites identified above.The North American Industry Classification System (NAICS) Code is 611310, Colleges, Universities, and Professional Schools and Code 541380, Testing LaboratoriesThe acquisition is being conducted under simplified acquisition FAR 13 and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this notification. This notice is for information and planning purposes only. THIS IS NOT A REQUEST FOR PROPOSALS. The Government does not intend to award a contract based on responses under this announcement. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing notification number NIHDA2012249 may be submitted no later than 12:00 p.m. Eastern Standard Time on Friday, February 10, 2012 to NIDA/IRP, Biomedical Research Center, Suite 200, 251 Bayview Boulevard, Room 4A326, Baltimore, MD 21224, ATTN: Carol Lindsay, clindsay@intra.nida.nih.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/3809148c29c5f32d20b79a044ae9139e)
- Record
- SN02662900-W 20120129/120127234649-3809148c29c5f32d20b79a044ae9139e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |